CeMOS now part of a Europe-wide research network in the field of drug discovery

Since 2019, the CeMOS research center (Center for Mass Spectrometry and Optical Spectroscopy) has also been increasingly active in international research. As part of the new Horizon 2020 EU project "EU-OPENSCREEN-DRIVE", public drug research is to be driven forward by modern technologies.

With currently 33 partners from 16 countries, including highly renowned research institutions such as the Karolinska Institute in Sweden and the Weizmann Institute in Israel, the EU-OPENSCREEN-DRIVE consortium offers a Europe-wide public research infrastructure for drug test systems and chemical biology. The main objectives of EU-OPENSCREEN are the creation of a drug library with more than 100,000 chemical and biological substances and their investigation in high-throughput test systems. Over a period of four years, the network will now be complemented with modern technologies.

In addition to SINTEF, one of the largest independent research organizations in Europe based in Norway, CeMOS will support public drug discovery with mass spectrometry techniques such as tissue imaging. The Bruker Centre at Mannheim University of Applied Sciences under the direction of Prof. Dr. Carsten Hopf offers an ideal platform with its state-of-the-art equipment.

"The participation in this excellent consortium confirms our strategy of transferring new technologies for drug discovery to industry and public use through worldwide contacts in the pharmaceutical industry and academic research," commented Prof. Hopf.

EU-OPENSCREEN-DRIVE is the second EU research project of the Mannheim University of Applied Sciences. The Hopf-working-group was already involved in the EU project "MITIGATE" in the field of medical research on gastrointestinal tumors from 2013 to 2017.